Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

BACKGROUND: Aberrant activation NF-kappaB has been proposed as a mechanism of drug resistance in pancreatic cancer. Recently, inhibition of glycogen synthase kinase-3 has been shown to exert anti-tumor effects on pancreatic cancer cells by suppressing NF-kappaB. Consequently, we investigated whether...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mamaghani, Shadi, Patel, Satish, Hedley, David W
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2009
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2685435/
https://ncbi.nlm.nih.gov/pubmed/19405981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-132
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak